PIoglitazone for PrEvention of Restenosis in Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00376870|
Recruitment Status : Unknown
Verified June 2008 by University of Rome Tor Vergata.
Recruitment status was: Recruiting
First Posted : September 15, 2006
Last Update Posted : August 1, 2008
Restenosis requiring reintervention is still a limitation of percutaneous coronary angioplasty. Despite the use of Drug eluting stent (DES), the rate of restenosis remains 7% to 16% in diabetic patients, making it a challenging problem in interventional cardiology.
Still, in clinical trials, most of these attempts did not successfully limit neointimal formation after coronary stenting.
Thiazolidinediones (TZDs), like pioglitazone (pio) or rosiglitazone, are a novel class of oral antidiabetic agents currently used to treat patients with type 2 diabetes mellitus.
These agents increase insulin sensitivity and, as such, have favorable effects on blood glucose levels and the lipid profile in treated patients.
Beyond their metabolic action, TZDs have been shown to exhibit antiinflammatory and antiatherogenic effects in vascular cells in vitro and to limit lesion development in various animal models of arteriosclerosis.
Moreover, TZDs inhibit VSMC proliferation and migration, 2 critical processes in neointimal formation after coronary stenting.
Data from rodent models suggest that TZDs limit intimal proliferation after vascular injury, and in clinical studies with type 2 diabetic coronary artery disease (CAD) patients, TZDs have been shown to reduce neointimal formation as well as restenosis after coronary stent implantation.
Still, it remains unclear to what extend these effects depend on the metabolic action of these drugs and what might mainly be due to the improvement in glycemic control.
Recently a few reports on prevention of restenosis in type 2 diabetic patients (T2DM) with the use of TZDs as been published. All of them uses BMS as endoprosthetic devices. None of these evaluated the use of TZDs in combination with DES.
Aim of the study is to evaluate the efficacy of pioglitazone in prevention of in-stent restenosis after successful implantation of a sirolimus-eluting coronary stent for treatment of de-novo "complex" coronary vessel disease in patients with T2DM and stable coronary artery disease.
Study primary end-point are late-loss at 9 months.Secondary end-point include binary restenosis MACE at 1, 9 and 12 month, stent thrombosis at 12 months.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Atherosclerosis Coronary Restenosis Diabetes||Drug: Pioglitazone Drug: Placebo||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent|
|Study Start Date :||July 2008|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||April 2011|
Active Comparator: Pioglitazone
pioglitazone 30 mg/d
|Placebo Comparator: Placebo||
Placebo 30 mg/d
- In-Segment Late Loss [ Time Frame: 9 months ]
- Binary restenosis [ Time Frame: 9 months ]
- MACE [ Time Frame: 1, 9, 12 month ]
- Stent thrombosis [ Time Frame: 12 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376870
|Contact: Fabrizio Clementi, MD, PhDemail@example.com|
|Contact: Ruggiero Mango, MDfirstname.lastname@example.org|
|Policlinico di Tor Vergata||Not yet recruiting|
|Rome, Italy, 00133|
|Principal Investigator: Fabrizio Clementi, MD. PhD|
|Policlinico di Tor Vergata||Recruiting|
|Rome, Italy, 00133|
|Contact: Saverio Muscoli, MD +390620904009 email@example.com|
|Principal Investigator: Fabrizio Clementi, MD, PhD|
|Study Chair:||Francesco Romeo, MD||University of Rome Tor Vergata|